Published in Pharmacol Rep on June 29, 2005
Therapeutic effect of vasoactive intestinal peptide on experimental autoimmune encephalomyelitis: down-regulation of inflammatory and autoimmune responses. Am J Pathol (2006) 1.19
Expanding the dipeptidyl peptidase 4-regulated peptidome via an optimized peptidomics platform. J Am Chem Soc (2010) 1.12
VIP and PACAP: neuropeptide modulators of CNS inflammation, injury, and repair. Br J Pharmacol (2013) 1.06
Treating brain tumors with PDE4 inhibitors. Trends Pharmacol Sci (2011) 1.05
RANTES upregulation in the Alzheimer's disease brain: a possible neuroprotective role. Neurobiol Aging (2008) 1.02
PACAP-38 induces neuronal differentiation of human SH-SY5Y neuroblastoma cells via cAMP-mediated activation of ERK and p38 MAP kinases. J Neurochem (2007) 1.01
VPAC receptors: structure, molecular pharmacology and interaction with accessory proteins. Br J Pharmacol (2012) 0.99
PACAP38 increases vesicular monoamine transporter 2 (VMAT2) expression and attenuates methamphetamine toxicity. Neuropeptides (2008) 0.98
Enhancing the GLP-1 receptor signaling pathway leads to proliferation and neuroprotection in human neuroblastoma cells. J Neurochem (2010) 0.97
Vasoactive intestinal peptide acts via multiple signal pathways to regulate hippocampal NMDA receptors and synaptic transmission. Hippocampus (2009) 0.91
Effect of PACAP in central and peripheral nerve injuries. Int J Mol Sci (2012) 0.89
PACAP protects against salsolinol-induced toxicity in dopaminergic SH-SY5Y cells: implication for Parkinson's disease. J Mol Neurosci (2013) 0.84
Targeting VIP and PACAP receptor signalling: new therapeutic strategies in multiple sclerosis. ASN Neuro (2011) 0.84
Future directions for immune modulation in neurodegenerative disorders: focus on Parkinson's disease. J Neural Transm (Vienna) (2010) 0.82
The functional state of hormone-sensitive adenylyl cyclase signaling system in diabetes mellitus. J Signal Transduct (2013) 0.81
Tuning immune tolerance with vasoactive intestinal peptide: a new therapeutic approach for immune disorders. Peptides (2007) 0.81
RANTES release contributes to the protective action of PACAP38 against sodium nitroprusside in cortical neurons. Neuropeptides (2009) 0.81
Corticotropin-releasing hormone exerts direct effects on neuronal progenitor cells: implications for neuroprotection. Mol Psychiatry (2013) 0.81
Inflammatory cells and cytokines in the olfactory bulb of a rat model of neuroinflammation; insights into neurodegeneration? J Interferon Cytokine Res (2013) 0.81
PACAP protects against TNFα-induced cell death in olfactory epithelium and olfactory placodal cell lines. Mol Cell Neurosci (2010) 0.80
Macrophage Resistance to HIV-1 Infection Is Enhanced by the Neuropeptides VIP and PACAP. PLoS One (2013) 0.79
Neuropeptides and Microglial Activation in Inflammation, Pain, and Neurodegenerative Diseases. Mediators Inflamm (2017) 0.79
Immunolocalization of Kisspeptin Associated with Amyloid-β Deposits in the Pons of an Alzheimer's Disease Patient. J Neurodegener Dis (2013) 0.78
The VPAC1 receptor: structure and function of a class B GPCR prototype. Front Endocrinol (Lausanne) (2012) 0.78
PACAP signaling exerts opposing effects on neuroprotection and neuroinflammation during disease progression in the SOD1(G93A) mouse model of amyotrophic lateral sclerosis. Neurobiol Dis (2013) 0.77
Postulated vasoactive neuropeptide immunopathology affecting the blood-brain/blood-spinal barrier in certain neuropsychiatric fatigue-related conditions: A role for phosphodiesterase inhibitors in treatment? Neuropsychiatr Dis Treat (2009) 0.76
Neuroprotective roles of pituitary adenylate cyclase-activating polypeptide in neurodegenerative diseases. BMB Rep (2014) 0.76
Therapeutic potential of vasoactive intestinal peptide and its receptors in neurological disorders. CNS Neurol Disord Drug Targets (2010) 0.76
Association of polymorphisms in neuroprotection and oxidative stress genes and neurodevelopmental outcomes after preterm birth. Obstet Gynecol (2012) 0.76
PACAP modulation of calcium ion activity in developing granule cells of the neonatal mouse olfactory bulb. J Neurophysiol (2014) 0.75
Neurotrophic and neuroprotective effects of oxyntomodulin in neuronal cells and a rat model of stroke. Exp Neurol (2016) 0.75
Hyaluronan: towards novel anti-cancer therapeutics. Pharmacol Rep (2013) 1.24
Paracetamol: mechanism of action, applications and safety concern. Acta Pol Pharm (2014) 0.95
Daily variation in the concentration of melatonin and 5-methoxytryptophol in the goose pineal gland, retina, and plasma. Gen Comp Endocrinol (2003) 0.92
[VEGF as an angiogenic, neurotrophic, and neuroprotective factor]. Postepy Hig Med Dosw (Online) (2005) 0.87
Rhythmic changes in metabolism of dopamine in the chick retina: the importance of light versus biological clock. J Neurochem (2003) 0.83
Orexins/hypocretins acting at Gi protein-coupled OX 2 receptors inhibit cyclic AMP synthesis in the primary neuronal cultures. J Mol Neurosci (2011) 0.82
[Age-related macular degeneration--a complex genetic disease]. Klin Oczna (2008) 0.81
[PEDF: an endogenous factor displaying potent neuroprotective, neurotrophic, and antiangiogenic activity]. Postepy Hig Med Dosw (Online) (2006) 0.80
Effects of PACAP and VIP on cAMP-generating system and proliferation of C6 glioma cells. J Mol Neurosci (2008) 0.80
PAC1 receptors in chick cerebral cortex: characterization by binding of pituitary adenylate cyclase-activating polypeptide, [125I]-PACAP27. Neurosci Lett (2003) 0.80
Cyclic AMP generating system in human microvascular endothelium is highly responsive to adrenaline. Pharmacol Rep (2007) 0.79
Effects of PACAP, VIP and related peptides on cyclic AMP formation in rat neuronal and astrocyte cultures and cerebral cortical slices. Pharmacol Rep (2007) 0.79
[The role of complement in physiology and pathology]. Postepy Hig Med Dosw (Online) (2007) 0.79
Orexins/hypocretins stimulate accumulation of inositol phosphate in primary cultures of rat cortical neurons. Pharmacol Rep (2013) 0.79
Constitutive activity of beta-adrenergic receptors in C6 glioma cells. Pharmacol Rep (2005) 0.78
Receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in turkey cerebral cortex: characterization by [125I]-VIP binding and effects on cyclic AMP synthesis. Gen Comp Endocrinol (2004) 0.77
Retinal illumination phase shifts the circadian rhythm of serotonin N-acetyltransferase activity in the chicken pineal gland. Neurosci Lett (2004) 0.77
[Antiinflammatory therapy in ostheoarthritis including omega 3 and omega 6 fatty acids]. Pol Merkur Lekarski (2012) 0.77
[Neuroprotective role of PACAP, VIP, and PHI in the central nervous system]. Postepy Hig Med Dosw (Online) (2004) 0.77
Rapid desensitization of receptors for pituitary adenylate cyclase-activating polypeptide (PACAP) in chick cerebral cortex. Pol J Pharmacol (2003) 0.77
Pertussis toxin-sensitive G protein modulates the ability of histamine to stimulate cAMP production in the chick pineal gland. Pol J Pharmacol (2004) 0.77
Receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in the goose cerebral cortex. Pol J Pharmacol (2004) 0.76
Histamine-induced cyclic AMP formation in the chick hypothalamus: interaction with vasoactive intestinal peptide. Pharmacol Rep (2005) 0.76
Suppression of melatonin biosynthesis in the chicken pineal gland by retinally perceived light - involvement of D1-dopamine receptors. J Pineal Res (2004) 0.76
[Pathogenesis and prophylaxis of AMD: focus on oxidative stress and antioxidants]. Postepy Hig Med Dosw (Online) (2010) 0.76
AMD--the retinal disease with an unprecised etiopathogenesis: in search of effective therapeutics. Acta Pol Pharm (2015) 0.76
Daily variation in the concentration of 5-methoxytryptophol and melatonin in the duck pineal gland and plasma. J Pineal Res (2002) 0.76
Posthatching developmental changes in noradrenaline content in the chicken pineal gland. J Pineal Res (2005) 0.76
Human micro- and macrovessel-derived endothelial cells: a comparative study on the effects of adrenaline and a selective adenosine A2-type receptor agonist under normoxic and hypoxic conditions. Pharmacol Rep (2008) 0.76
PACAP, VIP, and PHI: effects on AC-, PLC-, and PLD-driven signaling systems in the primary glial cell cultures. Ann N Y Acad Sci (2006) 0.75
Orexin A suppresses the growth of rat C6 glioma cells via a caspase-dependent mechanism. J Mol Neurosci (2012) 0.75
Effect of different forms of vasoactive intestinal peptide on cAMP formation in the mammalian cerebral cortex. Pol J Pharmacol (2004) 0.75
Characterization of histamine H(2)-like receptors in duck cerebral cortical membranes by [(3)H]tiotidine binding. Neurosci Lett (2002) 0.75
Characteristics of adrenaline-driven receptor-mediated signals in human microvessel-derived endothelial cells. Pharmacol Rep (2009) 0.75
Characterization of vasoactive intestinal peptide/pituitary adenylate cyclase-activating polypeptide receptors in chick cerebral cortex. J Mol Neurosci (2003) 0.75
Desensitization of H2-like histamine receptors stimulating cyclic AMP formation in the chick cerebral cortex. Pol J Pharmacol (2003) 0.75
[Bevacizumab: progress in the treatment of metastatic cancer and hope for patients with proliferative retinopathy]. Postepy Hig Med Dosw (Online) (2007) 0.75
[The neuroprotective effect of PACAP, VIP, and derivatives in brain ischemia]. Postepy Hig Med Dosw (Online) (2008) 0.75
Histamine H(2) -like receptors in chick cerebral cortex: effects on cyclic AMP synthesis and characterization by [(3) H]tiotidine binding. J Neurochem (2002) 0.75
The relationship between melatonin and dopamine rhythms in the duck retina. Neurosci Lett (2003) 0.75
Pharmacological properties and SAR of new 1,4-disubstituted piperazine derivatives with hypnotic-sedative activity. J Pharm Pharmacol (2002) 0.75
Effects of PEDF and VEGF on PACAP-/VIP-induced cAMP formation in rat brain derived astrocyte cultures. Pharmacol Rep (2009) 0.75
Cyclic AMP formation in chicken brain: effect of vasoactive intestinal peptide, peptide histidine-isoleucine (PHI), and some PHI-related peptides. Pol J Pharmacol (2004) 0.75
Pituitary adenylate cyclase-activating polypeptide (PACAP)-evoked increase in cyclic AMP production in chick cerebral cortex: lack of a role of the protein kinase C pathway. Pol J Pharmacol (2003) 0.75
[Peptide histidine-isoleucine and and its human analogue peptide histidine-methionine: localization, receptors and biological function]. Postepy Hig Med Dosw (Online) (2004) 0.75
Receptors for VIP and PACAP in guinea pig cerebral cortex: effects on cyclic AMP synthesis and characterization by 125I-VIP binding. J Mol Neurosci (2005) 0.75
Cyclic AMP formation in C6 glioma cells: effect of PACAP and VIP in early and late passages. Ann N Y Acad Sci (2006) 0.75